P-53: A MisAddressing-Free Triangular Color-pixel Arrangement Structure for High Efficacy ACPDPs

2003 ◽  
Vol 34 (1) ◽  
pp. 418 ◽  
Author(s):  
Jung Hun Kim ◽  
Byoung-Kuk Min ◽  
Hyun-il Park ◽  
Kwang-Yeol Choi
Keyword(s):  
High Efficacy ◽  
Color Pixel ◽  
P 53

P 53 and p56: A new signaling pathway in human endometrium and endometrial adenocarcinomas

1997 ◽  
Vol 4 (2) ◽  
pp. 103-109
Author(s):  
G COUCHMAN ◽  
R BENTLEY ◽  
M TSAO ◽  
K RASZMANN ◽  
J MCLACHLAN ◽  
...  
Keyword(s):  
Signaling Pathway ◽  
Human Endometrium ◽  
P 53

ОЦЕНКА ЭФФЕКТИВНОСТИ И БЕЗОПАСНОСТИ 10% ВНУТРИВЕННОГО ИММУНОГЛОБУЛИНА ПРИВИДЖЕН В РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКЕ

2019 ◽  
Author(s):  
L.G. Khludova ◽  
I.A. Manto ◽  
E.A. Latysheva ◽  
T.V. Latysheva ◽  
M.R. Khaitov
Keyword(s):  
Replacement Therapy ◽  
Primary Immunodeficiency ◽  
Adverse Reactions ◽  
Efficacy And Safety ◽  
High Efficacy ◽  
Antibody Synthesis ◽  
Human Immunoglobulins ◽  
Severe Adverse Reactions ◽  
Common Variable ◽  
Real Clinical Practice

Актуальность. Заместительная терапия иммуноглобулинами человека является ведущим патогенетическим методом лечения первичных иммунодефицитов с нарушением синтеза антител. В настоящее время в России доступно несколько препаратов иммуноглобулинов человека нормальных для внутривенного введения. Цель. Оценить эффективность и безопасность препарата Привиджен (10 раствор иммуноглобулина для внутривенного введения) в реальной клинической практике в течение 12 клинических месяцев. Материалы и методы. 20 взрослых с диагнозом общая вариабельная иммунная недостаточности и Х-сцепленная агаммаглобулинемия получали внутривенный иммуноглобулин Привиджен к интервалом 243 дня в течение 12 мес. Первичными критериями оценки была частота инфекционных осложнений и нежелательных явлений. Результаты. У большинства пациентов в ходе исследования достигнут удовлетворительный претранс-фузионный уровень IgG. Тяжелых нежелательных явлений, связанных с введением препарата, не зарегистрировано. Заключение. В ходе исследования препарат продемонстрировал высокую эффективность и безопасность у пациентов, нуждающихся в ежемесячной заместительной терапииRelevance. Replacement therapy with human immunoglobulins is the leading pathogenetic method of treatment of primary immunodeficiency with impaired antibody synthesis. Currently, several preparations of human immunoglobulins for intravenous administration are available in Russia. Purposes. Evaluation of the efficacy and safety of Privigen immunoglobulin intravenous 10 liquid in real clinical practice within 12 clinical months. Methods. Twenty adults diagnosed with common variable immunodeficiency or X-linked agammaglobulinemia received intravenous Privigen infusions (0.2-0.4 mg/kg) at 243 intervals over a 12-month period. The primary endpoint was the annual rate of infections and adverse events. Results. Sufficient level of IgG was achieved in most patients during the study. Severe adverse reactions during the treatment were not registered. Conclusions. High efficacy and safety of monthly replacement therapy in patients with primary immunodeficiency with impaired antibody synthesis has been demonstrated.

Small Molecular Gemcitabine Prodrugs for Cancer Therapy

2020 ◽  
Vol 27 (33) ◽  
pp. 5562-5582 ◽  
Author(s):  
He Miao ◽  
Xuehong Chen ◽  
Yepeng Luan
Keyword(s):  
Drug Resistance ◽  
Side Effects ◽  
Anticancer Drug ◽  
Drug Stability ◽  
Effective Means ◽  
Active Form ◽  
Deoxycytidine Kinase ◽  
High Efficacy ◽  
Pyrimidine Nucleoside ◽  
Design And Synthesis

Gemcitabine as a pyrimidine nucleoside analog anticancer drug has high efficacy for a broad spectrum of solid tumors. Gemcitabine is activated within tumor cells by sequential phosphorylation carried out by deoxycytidine kinase to mono-, di-, and triphosphate nucleotides with the last one as the active form. But the instability, drug resistance and toxicity severely limited its utilization in clinics. In the field of medicinal chemistry, prodrugs have proven to be a very effective means for elevating drug stability and decrease undesirable side effects including the nucleoside anticancer drug such as gemcitabine. Many works have been accomplished in design and synthesis of gemcitabine prodrugs, majority of which were summarized in this review.

P‐53: Development of Directly Stacked Dual‐Cell LCD with Mega Contrast

2021 ◽  
Vol 52 (1) ◽  
pp. 1269-1270
Author(s):  
Lin Zhang ◽  
Yanping Liao ◽  
Lei Guo ◽  
Ke Dai ◽  
Seungmin Li ◽  
...  
Keyword(s):  
P 53

scholarly journals First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience

ESMO Open ◽  
2021 ◽  
Vol 6 (2) ◽  
pp. 100065
Author(s):  
G. Jeryczynski ◽  
M. Antlanger ◽  
F. Duca ◽  
C. Binder-Rodriguez ◽  
T. Reiter ◽  
...  
Keyword(s):  
Real World ◽  
Al Amyloidosis ◽  
High Efficacy ◽  
First Line ◽  
The Real

scholarly journals High efficacy of tetra-PEG hydrogel sealants for sutureless dural closure

2021 ◽  
Author(s):  
Tengjiao Zhu ◽  
Hufei Wang ◽  
Zehao Jing ◽  
Daoyang Fan ◽  
Zhongjun Liu ◽  
...  
Keyword(s):  
High Efficacy ◽  
Dural Closure

scholarly journals How we manage smoldering multiple myeloma

2020 ◽  
Vol 12 (s1) ◽  
Author(s):  
Alessandra Romano ◽  
Claudio Cerchione ◽  
Concetta Conticello ◽  
Giovanni Martinelli ◽  
Francesco Di Raimondo
Keyword(s):  
Plasma Cells ◽  
Organ Damage ◽  
Prognostic Models ◽  
Clinical Approach ◽  
High Efficacy ◽  
Clinical Practices ◽  
Bone Marrow Plasma ◽  
Asymptomatic Stage ◽  
Smoldering Myeloma

Smoldering myeloma (SMM) is an asymptomatic stage characterized by bone marrow plasma cells infiltration between 10-60% in absence of myeloma-defining events and organ damage. Until the revision of criteria of MM to require treatment, two main prognostic models, not overlapping each other, were proposed and used differently in Europe and in US. Novel manageable drugs, like lenalidomide and monoclonal antibodies, with high efficacy and limited toxicity, improvement in imaging and prognostication, challenge physicians to offer early treatment to high-risk SMM. Taking advantage from the debates offered by SOHO Italy, in this review we will update the evidence and consequent clinical practices in US and Europe to offer readers a uniform view of clinical approach at diagnosis, follow-up and supportive care in the SMM setting.

Sign in / Sign up

Export Citation Format

Share Document